{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:02:57Z","timestamp":1789448577538,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    We present a case series of four patients with five splenic metastases treated with stereotactic body radiation therapy (SBRT) using a 1.5-T Unity (Elekta AB, Stockholm, Sweden) magnetic resonance linear accelerator (MR-Linac). While SBRT is a standard of care for the treatment of oligometastatic disease, splenic SBRT is not well established due to its rarity. MRI-guided adaptive radiotherapy (MRgART) offers superior soft tissue visualization and the unique ability to adapt treatment plans in real time. In our series, splenic oligometastases originated from primary malignancies of melanoma, colorectal adenocarcinoma, and non-small-cell lung cancer. Prescription doses ranged from 40 to 50 Gy in five fractions, with gross tumor volumes between 2.4 and 22.7 cm\n                    <jats:sup>3<\/jats:sup>\n                    . At 12 months, the local control was 80%. One patient developed grade 2 lymphopenia without infection following two courses SBRT with a total mean spleen dose of 24.4 Gy. Our experience suggests that MRgART is a technically feasible, effective, and non-invasive treatment for splenic metastases, offering excellent disease control with an acceptable toxicity profile. However, the benefits of splenic SBRT should be balanced against the potential risk of hematological toxicity, and prophylactic vaccinations for hyposplenism should be considered for this patient population.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1905280","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:26:56Z","timestamp":1789446416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: MR-guided adaptive stereotactic body radiotherapy for splenic metastases: a case series of technical feasibility and early clinical outcomes"],"prefix":"10.3389","volume":"16","author":[{"given":"D.","family":"Tan","sequence":"first","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]},{"name":"Faculty of Medicine and Health, The University of Sydney","place":["Camperdown, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Liang","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Biggerstaff","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Leong","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lim","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]},{"name":"Department of Surgery, UWA Medical School, The University of Western Australia","place":["Crawley, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rahim","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tan","sequence":"additional","affiliation":[{"name":"Genesis Care Murdoch","place":["Murdoch, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2018170119","article-title":"Cross-sectional imaging of splenic lesions: RadioGraphics fundamentals | online presentation","volume":"38","author":"Lee","year":"2018","journal-title":"RadioGraphics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0502-3","article-title":"Splenic metastases\u2014not a frequent problem, but an underestimate location of metastases: epidemiology and course","volume":"135","author":"Sauer","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230453","article-title":"A multicenter study of needle size and safety for splenic biopsy","volume":"310","author":"Kavandi","year":"2024","journal-title":"Radiology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2014.285","article-title":"Morbidity and mortality following elective splenectomy for benign and Malignant hematologic conditions: Analysis of the American College of Surgeons National Surgical Quality Improvement Program data","volume":"149","author":"Bagrodia","year":"2014","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.sopen.2020.06.004","article-title":"Splenectomy for benign and Malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes","volume":"2","author":"Alobuia","year":"2020","journal-title":"Surg Open Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132241","article-title":"Splenectomy in onco-hematologic patients: A retrospective study of early complications and 1-year mortality","volume":"17","author":"Faucher","year":"2025","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21037\/ales-20-90","article-title":"Open versus laparoscopic splenectomy a meta-analysis of larger series","volume":"5","author":"Sandri","year":"2020","journal-title":"Ann Laparoscopic Endoscopic Surg"},{"key":"B8","article-title":"Stereotactic body radiotherapy for an isolated splenic metastasis from ovarian carcinoma","volume":"6","author":"Hughes","year":"2019","journal-title":"J Radiosurg SBRT"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2019.12.005","article-title":"Stereotactic body radiation therapy to a splenic metastasis in oligoprogressive non-small cell lung cancer","volume":"5","author":"Kim","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"B10","article-title":"Splenic oligometastasis: Report of a patient successfully treated with stereotactic body radiation therapy","volume":"6","author":"Juloori","year":"2019","journal-title":"J Radiosurg SBRT"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.25259\/IJPC_101_2025","article-title":"Solitary splenic metastasis from gastric adenocarcinoma treated with stereotactic body radiotherapy using deep inspiratory breath hold","volume":"32","author":"Gupta","year":"2026","journal-title":"Indian J Palliat Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2016.1210738","article-title":"Isolated splenic metastasis from a thymic carcinoma: A case report","volume":"17","author":"Chen","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2025.05.008","article-title":"Can online adaptive radiation therapy eliminate intrafractional deformation in gastric mucosa-associated lymphoid tissue lymphoma","volume":"15","author":"Shibayama","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ctro.2021.09.004","article-title":"Analysis of data to advance personalised therapy with MR-Linac (ADAPT-MRL)","volume":"31","author":"de Leon","year":"2021","journal-title":"Clin Trans Radiat Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100816","article-title":"Does a peer review group consensus process for MR-Linac patients affect clinical care? Evaluation of impact and feasibility","volume":"48","author":"Sin","year":"2024","journal-title":"Clin Trans Radiat Oncol"},{"key":"B16","year":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100576","article-title":"Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer","volume":"39","author":"UChinami","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2023.100509","article-title":"Intra- and inter-fraction breath-hold variations and margins for radiotherapy of abdominal targets","volume":"28","author":"Ehrbar","year":"2023","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1569428","article-title":"Real-time tracking of lung tumors using a 1.5T Elekta Unity MR-Linac: First clinical experiences","volume":"15","author":"Smith","year":"2025","journal-title":"Front Oncol"},{"key":"B20","unstructured":"Incidental Irradiation of the Spleen - RCR Guidance"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2025.101011","article-title":"Changes in splenic volumes following stereotactic ablative radiotherapy (SABR) to adrenal tumors","volume":"54","author":"Giraud","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S179902","article-title":"Post-splenectomy sepsis: Preventative strategies, challenges, and solutions","volume":"12","author":"Luu","year":"2019","journal-title":"Infect Drug Resist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1905280\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:26:58Z","timestamp":1789446418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1905280\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1905280"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1905280","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1905280"}}